UB

Upstream Bio, Inc.

UPB·NASDAQ

$20.97

-5.9%
HealthcareBiotechnology

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

At a Glance

Live Snapshot
Market Cap$1.13B
EPS-0.7400
P/E Ratio-3.69
Earnings Date11/06/2025

upb

Sales/Maturities of Investments

Last Annual Value

231.63M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

UB

Upstream Bio, Inc. Competitors Analysis of Sales/Maturities of Investments

UPB · NASDAQ
CompanySales/Maturities of Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
231.63M
71.0%N/AN/A 
312.39M
59.0%28.3%N/A
312.72M
100.2%66.1%N/A
101.18M
-8.6%50.7%N/A
316.18M
-21.2%-9.8%N/A
SEPN logo
Septerna, Inc.
NASDAQ:SEPN
209.62M
N/AN/AN/A
200.89M
N/AN/AN/A
0.00
N/AN/AN/A
284.68M
-24.1%-24.7%1.0%
0.00
N/AN/AN/A
UB

Upstream Bio, Inc. Fair Value Envelope

UPB · NASDAQ

Our analysis suggests that UPB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $20.97, this represents a potential HIDDEN relative to our calculated worth for Upstream Bio, Inc..

Intrinsic Value
Current Price: $20.97